-+ 0.00%
-+ 0.00%
-+ 0.00%

Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21

Benzinga·08/14/2026 17:00:22
Listen to the news
Oppenheimer analyst Jeff Jones maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and lowers the price target from $22 to $21.